5/28/2014 9:18:38 AM
NEW YORK & LAVAL, Canada--(BUSINESS WIRE)--Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced that the KIACTA™ Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by